Skip to main content

Table 2 Univariate analysis for progression free survival in our cohort

From: EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

CharacteristicsUnivariate analyses
HR (95% CI)P value
Age at start of osimertinib, years
  < 601.00 (Reference) 
  ≥ 600.75 (0.38–1.51)0.425
 Female1.00 (Reference) 
 Male1.24 (0.62–2.47)0.548
 Never1.00 (Reference) 
 Ever1.40 (0.64–3.07)0.401
 Unknown1.51 (0.19–11.80)0.692
Brain metastases
 Yes1.00 (Reference) 
 None0.72 (0.36–1.43)0.345
Line of therapy 
 1st/2nda1.00 (Reference) 
 3rd or more1.05 (0.49–2.24)0.900
NGS platform
 BGIb1.00 (Reference) 
 OrigiMed1.19 (0.61–2.34)0.612
EGFR activating mutation
 Exon 19 deletion1.00 (Reference) 
 Exon 21 L858R1.21 (0.57–2.56)0.618
 Lower than the median MSAF1.00 (Reference) 
 Higher than the median MSAF0.73 (0.37–1.45)0.373
TP53 status
 Mutated1.00 (Reference) 
 Wild type0.53 (0.25–1.11)0.092
 T790M RMA (continuous)0.40 (0.14–1.16)0.091
 T790M RMP (continuous)0.14 (0.04–0.56)0.005
T790M RMA (categorical)
 ≤ 0.301.00 (Reference) 
 > 0.300.43 (0.22–0.85)0.015
T790M RMP (categorical)
 ≤ 0.241.00 (Reference) 
  > 0.240.36 (0.18–0.72)0.004
  1. HR hazard ratio, CI confidence interval, NGS next-generation sequencing, EGFR epidermal growth factor receptor, MSAF maximum somatic allele frequency, RMA Relative mutation abundance, RMP Relative mutation purity
  2. aThree patients had de novo T790M mutation and osimertinib were the first-line therapy
  3. bTwo samples analyzed with an upgrading BGI OseqT NGS panel